These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 37093270)

  • 1. Increased mRNA expression of CDKN2A is a transcriptomic marker of clinically aggressive meningiomas.
    Wang JZ; Patil V; Liu J; Dogan H; Tabatabai G; Yefet LS; Behling F; Hoffman E; Bunda S; Yakubov R; Kaloti R; Brandner S; Gao A; Cohen-Gadol A; Barnholtz-Sloan J; Skardelly M; Tatagiba M; Raleigh DR; Sahm F; Boutros PC; Aldape K; ; Nassiri F; Zadeh G
    Acta Neuropathol; 2023 Jul; 146(1):145-162. PubMed ID: 37093270
    [TBL] [Abstract][Full Text] [Related]  

  • 2. p16 Immunohistochemistry as a Screening Tool for Homozygous CDKN2A Deletions in CNS Tumors.
    Zschernack V; Andreiuolo F; Dörner E; Wiedey A; Jünger ST; Friker LL; Maruccia R; Pietsch T
    Am J Surg Pathol; 2024 Jan; 48(1):46-53. PubMed ID: 37947008
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alterations of the tumor suppressor genes CDKN2A (p16(INK4a)), p14(ARF), CDKN2B (p15(INK4b)), and CDKN2C (p18(INK4c)) in atypical and anaplastic meningiomas.
    Boström J; Meyer-Puttlitz B; Wolter M; Blaschke B; Weber RG; Lichter P; Ichimura K; Collins VP; Reifenberger G
    Am J Pathol; 2001 Aug; 159(2):661-9. PubMed ID: 11485924
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CDKN2A/B homozygous deletion is associated with early recurrence in meningiomas.
    Sievers P; Hielscher T; Schrimpf D; Stichel D; Reuss DE; Berghoff AS; Neidert MC; Wirsching HG; Mawrin C; Ketter R; Paulus W; Reifenberger G; Lamszus K; Westphal M; Etminan N; Ratliff M; Herold-Mende C; Pfister SM; Jones DTW; Weller M; Harter PN; Wick W; Preusser M; von Deimling A; Sahm F
    Acta Neuropathol; 2020 Sep; 140(3):409-413. PubMed ID: 32642869
    [No Abstract]   [Full Text] [Related]  

  • 5. Analysis of CDKN2A gene alterations in recurrent and non-recurrent meningioma.
    Guyot A; Duchesne M; Robert S; Lia AS; Derouault P; Scaon E; Lemnos L; Salle H; Durand K; Labrousse F
    J Neurooncol; 2019 Dec; 145(3):449-459. PubMed ID: 31729637
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correlation of MTAP Immunohistochemistry With CDKN2A Status Assessed by Fluorescence In Situ Hybridization and Clinicopathological Features in CNS WHO Grade 2 and 3 Meningiomas: A Single Center Cohort Study.
    Sasaki S; Takeda M; Hirose T; Fujii T; Itami H; Uchiyama T; Morita K; Matsuda R; Yamada S; Nakagawa I; Ohbayashi C
    J Neuropathol Exp Neurol; 2022 Jan; 81(2):117-126. PubMed ID: 34897475
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Loss of p16 expression is a sensitive marker of CDKN2A homozygous deletion in malignant meningiomas.
    Tang V; Lu R; Mirchia K; Van Ziffle J; Devine P; Lee J; Phillips JJ; Perry A; Raleigh DR; Lucas CG; Solomon DA
    Acta Neuropathol; 2023 Apr; 145(4):497-500. PubMed ID: 36723772
    [No Abstract]   [Full Text] [Related]  

  • 8. [Methylthioadenosine phosphorylase and p16 as surrogate diagnostic markers for CDKN2A homozygous deletion in brain tumors].
    Wang SN; Wang W; Zhang XW; Zhang YQ; Xiong YL; Liu L; Teng LH
    Zhonghua Bing Li Xue Za Zhi; 2024 May; 53(5):439-445. PubMed ID: 38678323
    [No Abstract]   [Full Text] [Related]  

  • 9. CDKN2A/B deletions are strongly associated with meningioma progression: a meta-analysis of individual patient data.
    Wach J; Basaran AE; Arlt F; Vychopen M; Seidel C; Barrantes-Freer A; Müller W; Gaunitz F; Güresir E
    Acta Neuropathol Commun; 2023 Nov; 11(1):189. PubMed ID: 38017560
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Distinct genomic subclasses of high-grade/progressive meningiomas: NF2-associated, NF2-exclusive, and NF2-agnostic.
    Williams EA; Santagata S; Wakimoto H; Shankar GM; Barker FG; Sharaf R; Reddy A; Spear P; Alexander BM; Ross JS; Brastianos PK; Cahill DP; Ramkissoon SH; Juratli TA
    Acta Neuropathol Commun; 2020 Oct; 8(1):171. PubMed ID: 33087175
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advances in Molecular Biological and Translational Studies in World Health Organization Grades 2 and 3 Meningiomas: A Literature Review.
    Okano A; Miyawaki S; Teranishi Y; Ohara K; Hongo H; Sakai Y; Ishigami D; Nakatomi H; Saito N
    Neurol Med Chir (Tokyo); 2022 Aug; 62(8):347-360. PubMed ID: 35871574
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epigenetic and genomic profiling of chordoid meningioma: implications for clinical management.
    Daoud EV; Zhu K; Mickey B; Mohamed H; Wen M; Delorenzo M; Tran I; Serrano J; Hatanpaa KJ; Raisanen JM; Snuderl M; Cai C
    Acta Neuropathol Commun; 2022 Apr; 10(1):56. PubMed ID: 35440040
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular prognostication in grade 3 meningiomas and p16/MTAP immunohistochemistry for predicting
    Tosefsky K; Martin KC; Rebchuk AD; Wang JZ; Nassiri F; Lum A; Zadeh G; Makarenko S; Yip S
    Neurooncol Adv; 2024; 6(1):vdae002. PubMed ID: 38288091
    [TBL] [Abstract][Full Text] [Related]  

  • 14. P16 immunohistochemistry is a sensitive and specific surrogate marker for CDKN2A homozygous deletion in gliomas.
    Vij M; Cho BB; Yokoda RT; Rashidipour O; Umphlett M; Richardson TE; Tsankova NM
    Acta Neuropathol Commun; 2023 May; 11(1):73. PubMed ID: 37138345
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of MTAP and p16 immunohistochemical deficiency as surrogate marker for CDKN2A/B homozygous deletion in gliomas.
    Maragkou T; Reinhard S; Jungo P; Pasquier B; Neuenschwander M; Schucht P; Vassella E; Hewer E
    Pathology; 2023 Jun; 55(4):466-477. PubMed ID: 37032198
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-Grade Endometrial Stromal Sarcomas With YWHAE::NUTM2 Gene Fusion Exhibit Recurrent CDKN2A Alterations and Absence of p16 Staining is a Poor Prognostic Marker.
    Kommoss FKF; Mar LM; Howitt BE; Hanley K; Turashvilli G; Buslei R; Irving JA; Dickson BC; Koelsche C; Sinn HP; Schirmacher P; von Deimling A; Chiang S; McCluggage WG; Croce S; Stewart CJR; Lee CH
    Mod Pathol; 2023 Mar; 36(3):100044. PubMed ID: 36788095
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CDKN2A gene deletions and loss of p16 expression occur in osteosarcomas that lack RB alterations.
    Nielsen GP; Burns KL; Rosenberg AE; Louis DN
    Am J Pathol; 1998 Jul; 153(1):159-63. PubMed ID: 9665476
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A role for chromosome 9p21 deletions in the malignant progression of meningiomas and the prognosis of anaplastic meningiomas.
    Perry A; Banerjee R; Lohse CM; Kleinschmidt-DeMasters BK; Scheithauer BW
    Brain Pathol; 2002 Apr; 12(2):183-90. PubMed ID: 11958372
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Simultaneous aberrations of single CDKN2A network components and a high Rb phosphorylation status can differentiate subgroups of primary cutaneous B-cell lymphomas.
    Kaune KM; Neumann C; Hallermann C; Haller F; Schön MP; Middel P
    Exp Dermatol; 2011 Apr; 20(4):331-5. PubMed ID: 21410763
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CDKN2A mutations have equivalent prognostic significance to homozygous deletion in IDH-mutant astrocytoma.
    Yokoda RT; Cobb WS; Yong RL; Crary JF; Viapiano MS; Walker JM; Umphlett M; Tsankova NM; Richardson TE
    J Neuropathol Exp Neurol; 2023 Sep; 82(10):845-852. PubMed ID: 37550258
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.